New Delhi: Redcliffe Labs announced the strategic divestment of Crysta IVF to Moon Care Private Limited, the healthcare arm of MMG Group.
The move marks a significant milestone for Crysta IVF while enabling Redcliffe Labs to strengthen its core focus on diagnostics and preventive healthcare services.
The transaction reflects Redcliffe Labs’ continued commitment to expanding its footprint in advanced diagnostics and preventive care. By divesting Crysta IVF, the company aims to consolidate its efforts toward delivering technology-led, accessible, accurate, and affordable diagnostic solutions at scale across India.
Crysta IVF Achieved EBITDA Profitability at Start of FY26: Positioned to Continue Growth Trajectory
The transition is expected to further enhance Crysta IVF’s focus on specialized fertility care and broaden access to reproductive health services nationwide.
Also Read: Dr. Sonal Saxena Appointed Director – Lab Operations at Redcliffe Labs
Aditya Kandoi, Founder & CEO, Redcliffe Labs, said: “Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare – with the goal of adding healthier years to people’s lives. This divestment allows us to sharpen that focus even further.
For Dheeraj (Co-founder, Redcliffe Labs) and me, Crysta IVF has been a meaningful part of our journey. What started as an Operate & Manage model in 2021 evolved into a scalable network of high-quality, self-owned centres, achieving profitability in a relatively short time.
We are proud of the foundation that has been built, and we’re confident that under Moon Care Private Limited’s leadership, Crysta IVF will continue to expand its impact in fertility care.”
The acquisition marks MMG Group’s entry into the healthcare sector. Sanjeev Agarwal, Chairman, MMG Group, stated: “We are delighted to welcome Crysta IVF into the Moon Care ecosystem. Our focus will be on making fertility care even more accessible and deeply technology-driven.
Crysta IVF has earned the trust of thousands of families, and we see a strong opportunity to build on this foundation – expanding access to high-quality fertility treatments across the country while continuing to enhance patient experience and outcomes.
This marks MMG Group’s first step into healthcare, a sector where we believe we can create meaningful impact by improving access and outcomes at scale.”
Also Read: Blood Print of Your City: Redcliffe Labs Decodes India’s City-Level Health Data
Advisory firm Alvarez & Marsal acted as the exclusive advisor to the transaction. Commenting on the deal, Mohit Khullar, Managing Director and Head of Corporate Finance – India, said: “This transaction underscores strong investor confidence in the healthcare services ecosystem and reinforces the growth potential of Crysta within the IVF segment. We are grateful to all stakeholders for their trust and collaboration in delivering a successful outcome.”
For existing patients, Crysta IVF has confirmed that the transition will be seamless, with no disruption to ongoing treatments or services. The current team and leadership of Crysta IVF will continue to manage operations, working closely with Moon Care Private Limited to ensure continuity of care while introducing new initiatives aimed at improving patient outcomes.
For Redcliffe Labs, the divestment of Crysta IVF signifies a sharpened focus on its diagnostics business. This strategic move will enable the company to accelerate expansion, increase testing volumes, and deepen its presence in preventive healthcare, thereby driving greater impact through early detection and accessible care.
